Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01627678
Other study ID # CTN-BI-Vacc-C5-2011/1
Secondary ID 2012-000710-11
Status Completed
Phase Phase 1/Phase 2
First received June 21, 2012
Last updated January 13, 2014
Start date September 2012
Est. completion date November 2013

Study information

Verified date January 2014
Source Bionor Immuno AS
Contact n/a
Is FDA regulated No
Health authority Norway: Norwegian Medicines Agency
Study type Interventional

Clinical Trial Summary

Background:

Despite the introduction of highly effective antiretroviral therapy (ART) regimes, which control the HIV infection and results in increases in CD4 cell counts and an undetectable viral load, many patients suffer from increased morbidity. There is evidence that presence of antibodies against the C5 region of gp120 strongly correlates with slower disease progression, and that loss of antibody responses to this region are associated with progression.

Investigational product:

Vacc-C5 is a single heterodimeric peptide-based HIV therapeutic vaccine corresponding to the C5 region on gp120 and the external domain of gp41. The vaccine is intended to create a non-neutralizing antibody against C5 region.

Study objectives:

1. To evaluate safety of the vaccination regimens

2. To evaluate C5-specific humoral immune responses (antibodies), T cell responses, T cell activation markers and other immune markers.


Description:

Background:

Despite the introduction of highly effective antiretroviral therapy (ART) regimes, which control the HIV infection and results in increases in CD4 cell counts and an undetectable viral load, many patients suffer from increased morbidity. There is evidence that presence of antibodies against the C5 region of gp120 strongly correlates with slower disease progression, and that loss of antibody responses to this region are associated with progression.

Investigational product:

Vacc-C5 is a single heterodimeric peptide-based HIV therapeutic vaccine corresponding to the C5 region on gp120 and the external domain of gp41. The rationale behind the Vacc-C5 is the finding that long-term non-progressors (LTNP) subjects have more antibodies towards the C5 part of gp120 than HIV infected subjects with a more rapid disease progression.

The primary objective of Vacc-C5 immunotherapy is to induce a humoral immune response. The vaccine is intended to create a non-neutralizing antibody against the C5 region and to thereby mimic a natural process in HIV-infected long-term non-progressors (LTNP) subjects.

Use of adjuvant:

Peptide vaccines are poorly immunogenic by themselves. To induce measurable levels of T helper cell type 1 (Th1) or type 2 (Th2) immune responses against these peptides, an adjuvant is often required.

Two different adjuvants are to be used in this study:

1. GM-CSF which facilitates dendritic cell maturation and migration to the lymph nodes for antigen presentation. The regimen when using this adjuvant is intradermal administration.

2. Aluminum-containing adjuvants is well known. They have been administered to human beings and animals in millions of doses of vaccines. This type of vaccine is usually administered intramuscularly or subcutaneously. In this study intramuscular administration will be used.

Primary objective:

It is to evaluate the safety of Vacc-C5 at three different dose levels given intradermally with GM-CSF as adjuvant or given intramuscularly with Alhydrogel as adjuvant.

Secondary objectives:

1. To evaluate C5-specific humoral immune responses (antibodies).

2. To evaluate the C5-specific T cell responses by ELISPOT and T cell proliferation.

3. To evaluate T cell activation markers (e.g. CD38, HLA-DR) and other immune markers.

Study design:

The study is an open, dose-escalating, single centre study in HIV-positive subjects on treatment (ART). Two different vaccine regimens will be tested:

1. Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.

2. Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.

Three dose levels of Vacc-C5 (100, 300 and 900 microgram will be tested for each of the two vaccination regimen. A dose escalation design (3+3) will be used, and if no dose limiting toxicity (DLT) is detected 18 subjects will be included in each arm.

Subjects who have been HIV-positive and stable on ART for the last 6 months with CD4 cell counts ≥400x 10 6 /L and who meet the other inclusion and exclusion criteria will be eligible for the study. The duration of the study is 26 weeks plus a screening period of up to 12 weeks.

During the Treatment Period, all subjects will remain on their ART and receive three immunizations; at Weeks 1, 2 and 4, with Vacc C5 including either GM-CSF or Alhydrogel as adjuvant.

The study is sequential, meaning that the first three subjects in each arm receive the lowest dose (three subjects) 100 µg Vacc-C5. If no dose limiting toxicity has been detected after week 4 vaccination, three more subjects will be added and the next dose level will be started.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date November 2013
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Age between18 years and 55 years, both genders.

- HIV positive at least one year.

- Clinically stable on ART for the last 6 months (changes in therapy is allowed as long as the viral load is stable).

- Documented viral load (HIV-1 RNA) less than 50 copies/mL for the last six months. Single blips (up to 500 copies/mL) are allowed.

- Documented pre-study CD4 cell count = 400x106/L for at least six months (if below at screening, a re-analysis is allowed).

- Nadir (lowest ever) CD4 cell count = 200x106/L (nadir below 200x106/L requires two consecutive analyses).

- Signed informed consent.

Exclusion Criteria:

- Reported pre-study AIDS-defining illness within the previous year

- Malignant disease.

- On chronic treatment with immunosuppressive therapy.

- Unacceptable values of the hematologic and clinical chemistry parameters, as judged by the Principle Investigator (or designee), including creatinine values >1.5x upper limit of normal (ULN), and AST (SGOT), ALT (SGPT) and alkaline phosphatase values >2.5x ULN.

- Concurrent chronic active infection such as viral hepatitis B or C or tuberculosis.

- Pregnant or breastfeeding women.

- Women of childbearing potential not using reliable and adequate contraceptive methods (defined as: use of oral, implanted, injectable, mechanical or barrier products for the prevention of pregnancy; practicing abstinence; sterile) during the study, or sexually active male subjects with partners of childbearing potential unwilling to practice effective contraception during the study.

- Current participation in other clinical therapeutic studies.

- Incapability of compliance to the treatment protocol, in the opinion of the Investigator.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Vacc-C5/GM-CSF
Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
Vacc-C5/Alhydrogel
Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.

Locations

Country Name City State
Norway Oslo University Hospital, Ullevål Oslo

Sponsors (1)

Lead Sponsor Collaborator
Bionor Immuno AS

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety measured as change of AE records, clinical chemistry (incl. CD4, CD8, HIV-1 RNA)and hematology laboratory elevations AEs recorded at each scheduled and unscheduled visit.
Concomitant medications recorded at each scheduled visit.
Vital signs (heart rate, blood pressure) at screening, weeks 1, 4, 6, 12, 13, 15, 21, 22 and 26 (End of study).
Weight at screening and weight at weeks 1, 12 and 26 (End of study).
Clinical laboratory evaluations (clinical chemistry, hematology) at screening, weeks 1, 4, 6, 12, 15, 21 and 26 (End of study).
Viral load (HIV-1 RNA) at screening, weeks 1, 6, 15 and 26 (End of study).
Urine stix at weeks 1, 4, 6, 12, 15, 21 and 26 (End of study).
From screening and week 1 to weeks 2, 4, 6, 12, 13, 15, 21, 22 and 26 Yes
Secondary Change in Humoral and T cell responses Humoral immune response - C5 antibody level at screening, weeks 1, 4, 6, 12, 13, 15, 21, 22 and 26 (End of study).
B cell antibody level at weeks 1, 6, 13 and 22.
T cell response and activation markers (e.g. CD38, HLA-DR) and other immune markers at weeks 1, 6, 15and 26 (End of study).
From screening and week 1 to weeks 4, 6, 12, 13, 15, 21, 22 and 26 No
See also
  Status Clinical Trial Phase
Completed NCT03188523 - Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) Phase 1
Active, not recruiting NCT06185452 - Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine Phase 4
Recruiting NCT02881320 - Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 Phase 2/Phase 3
Completed NCT02542852 - A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia Phase 2
Completed NCT02513771 - Sitagliptin for Reducing Inflammation and Immune Activation Phase 2
Terminated NCT02732457 - Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients
Completed NCT02057796 - Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Phase 4
Completed NCT01989910 - Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Phase 4
Completed NCT01704781 - Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) Phase 1/Phase 2
Completed NCT01403051 - High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART Phase 2
Completed NCT01466595 - Rifaximin as a Modulator of Microbial Translocation and Immune Activation Phase 2
Completed NCT01348308 - Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Phase 3
Completed NCT01511809 - Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression Phase 3
Completed NCT01019551 - Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients Phase 2
Terminated NCT01130376 - Novel Interventions in HIV-1 Infection Phase 1
Completed NCT00323687 - SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada Phase 4
Completed NCT04003103 - Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) Phase 2
Completed NCT02527096 - A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol) Phase 2
Active, not recruiting NCT04776252 - Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) Phase 3
Completed NCT02174159 - Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003) Phase 1